---
title: "Sino Biopharm says NMPA clears TQF6422 obesity drug candidate for clinical trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296603125.md"
description: "Sino Biopharmaceutical's unit, Chia Tai Tianqing, has received clearance from China's National Medical Products Administration (NMPA) to initiate clinical trials for TQF6422. This ActRII A/B-targeting monoclonal antibody is being developed as an obesity injection for weight management in obese adults or overweight individuals with comorbidities."
datetime: "2026-08-21T10:17:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296603125.md)
  - [en](https://longbridge.com/en/news/296603125.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296603125.md)
generator: "portal-rs"
---

# Sino Biopharm says NMPA clears TQF6422 obesity drug candidate for clinical trial

-   Sino Biopharmaceutical unit Chia Tai Tianqing secured NMPA clearance to start clinical studies of TQF6422 obesity injection. \* ActRII A/B-targeting monoclonal antibody to be tested for weight management in obese adults, or overweight adults with at least one comorbidity. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12294335), on August 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [01177.HK](https://longbridge.com/en/quote/01177.HK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)

## Related News & Research

- [Sino Biopharm wins NMPA nod to start LM-364 Nectin-4 TME ADC trial in solid tumors](https://longbridge.com/en/news/297289638.md)
- [Sino Biopharma wins FDA clearance to start trial of CPX301 GLP-1 weight-loss microneedle patch](https://longbridge.com/en/news/296857285.md)
- [SBP GROUP 's Innovative ActRII A/B Monoclonal Antibody Approved for Clinical Study](https://longbridge.com/en/news/296699167.md)
- [Sino Biopharma rebrands as SBP Group, targets global expansion via direct commercial rollout and partnerships](https://longbridge.com/en/news/296447837.md)
- [SBP GROUP  Interim Net Profit Rises 1.4% YoY to RMB3.43B; Div 7 HK Cents](https://longbridge.com/en/news/296327356.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**